Xenon Pharma director exercises 5,144 options

Xenon Pharmaceuticals director Dawn Svoronos exercised vested stock options, increasing her direct Common Share holdings.

Rhea-AI Filing Summary

Xenon Pharmaceuticals Inc. (XENE) director Dawn Svoronos exercised stock options for 5,144 Common Shares on September 1, 2026 at an exercise price of $8.15 per share, converting fully vested options into shares. Following the exercise, she holds 31,373 Common Shares directly, and no related Rule 10b5-1 trading plan is reported.

Insider Trade Summary

5,144 shares exercised/converted

Exercise 2 txns

Insider Svoronos Dawn

Role Director

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy) F1	5,144	$0.00	$0.00
Exercise	Common Shares	5,144	$8.15	$42K

Holdings After Transaction: Stock Option (Right to Buy) — 0 contracts (Direct); Common Shares — 31,373 shares (Direct)

Footnotes (1)

1. F1. The shares subject to the option are fully vested and exercisable.

Key Figures

Shares exercised: 5,144 shares Exercise price: $8.15 per share Shares owned after transaction: 31,373 shares +2 more

5 metrics

Shares exercised 5,144 shares Stock option exercise by director on September 1, 2026

Exercise price $8.15 per share Exercise of Stock Option (Right to Buy) into Common Shares

Shares owned after transaction 31,373 shares Direct Common Share holdings of Dawn Svoronos after exercise

Option expiration date September 26, 2026 Expiration date of the exercised stock option before conversion

Derivative shares exercised 5,144 shares Stock Option (Right to Buy) fully exercised, leaving no derivative position

Key Terms

Stock Option (Right to Buy), derivative security, Common Shares, Rule 10b5-1

4 terms

Stock Option (Right to Buy) financial

"security titled "Stock Option (Right to Buy)" was exercised for 5,144 shares"

derivative security financial

"transaction is described as an exercise or conversion of a derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

Common Shares financial

"underlying security and resulting holdings are described as Common Shares"

Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

Rule 10b5-1 regulatory

"no Rule 10b5-1 trading plan is reported for these transactions"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Xenon Pharmaceuticals (XENE) report for Dawn Svoronos?

Xenon Pharmaceuticals reported that director Dawn Svoronos exercised stock options for 5,144 Common Shares on September 1, 2026 at an exercise price of $8.15 per share, increasing her direct share ownership.

How many Xenon Pharmaceuticals (XENE) shares does Dawn Svoronos own after this Form 4?

After the reported transactions, Dawn Svoronos directly owns 31,373 Common Shares of Xenon Pharmaceuticals. The exercised options for 5,144 shares are no longer outstanding as a derivative position.

What type of derivative security did Dawn Svoronos exercise in Xenon Pharmaceuticals (XENE)?

She exercised a Stock Option (Right to Buy) covering 5,144 Common Shares. The filing notes that the shares subject to the option were fully vested and exercisable before this transaction.

Was the Xenon Pharmaceuticals (XENE) insider transaction made under a Rule 10b5-1 plan?

No. The Form 4 indicates the Rule 10b5-1 checkbox is not marked, so no Rule 10b5-1 trading plan is reported in connection with these transactions.

What were the key dates and prices in this Xenon Pharmaceuticals (XENE) Form 4?

The option exercise and related share acquisition occurred on September 1, 2026. The exercise price for the stock option was $8.15 per share, and the option had an expiration date of September 26, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/03/2026 - 08:27 PM EDT Accepted by SEC EDGAR 09/03/2026 - 08:26 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Svoronos Dawn

(Last) (First) (Middle)

3650 GILMORE WAY

(Street)

BURNABY V5G 4W8

(City) (State) (Zip)

BRITISH COLUMBIA, CANADA

(Country)

2. Issuer Name and Ticker or Trading Symbol
Xenon Pharmaceuticals Inc. [ XENE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	09/01/2026		M		5,144	A	$8.15	31,373	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$8.15	09/01/2026		M			5,144	(1)	09/26/2026	Common Shares	5,144	$0	0	D

Explanation of Responses:

1. The shares subject to the option are fully vested and exercisable.

	/s/ Nathaniel Adams, Attorney-in-fact	09/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)